{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:07:37Z","timestamp":1776107257215,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R00CA245900"],"award-info":[{"award-number":["R00CA245900"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The U.S. Preventive Services Task Force recommends that men aged 55\u201369\u00a0years undergo shared decision-making (SDM) regarding prostate cancer (PCa) screening, and routine screening is not recommended for older men or those with limited life expectancy. We evaluated the association between individual life expectancy and the receipt and content of SDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified male respondents aged\u2009\u2265\u200950\u00a0years and older without a history of PCa within the 2020 Behavioral Risk Factor Surveillance System survey. SDM was defined as whether a healthcare professional had ever discussed the advantages and\/or disadvantages of a prostate-specific antigen test with the respondent. Life expectancy was estimated based on a validated index incorporating respondent age, comorbidities, and activities of daily living. Adjusted odds ratios (aOR) were estimated for the associations between respondent age, life expectancy, and receipt of SDM, accounting for healthcare access and utilization-related factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Reported receipt of any SDM was highest among 70\u201374-year-old men (62.6%, 95% CI 60.5\u201364.6%). In multivariable models, those with the lowest life expectancy were modestly less likely to receive SDM (aOR\u2009=\u20090.84, 95% CI 0.71\u20130.99, Q4 vs Q1) compared to those with the greatest life expectancy. SDM discussing only the advantages of screening was the most common form of SDM; the content of SDM conversations did not differ by age or life expectancy, and 14.5% of men who were recently screened reported no prior SDM whatsoever.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Life expectancy appears to be inadequately incorporated into decision-making regarding PCa screening. Additional tools are needed to support SDM conversations to improve the population benefits\u2013harms of PCa screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10552-025-02069-1","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T09:01:04Z","timestamp":1757494864000},"page":"1891-1900","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of life expectancy on shared decision-making for prostate cancer screening"],"prefix":"10.1007","volume":"36","author":[{"given":"Myles M.","family":"Reed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenakshi","family":"Davuluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bashir","family":"Al Hussein Al Awamlh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin H.","family":"Kensler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"2069_CR1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/ju.0000000000000346","volume":"202","author":"R Gulati","year":"2019","unstructured":"Gulati R, Psutka SP, Etzioni R (2019) Personalized risks of over diagnosis for screen detected prostate cancer incorporating patient comorbidities: estimation and communication. J Urol 202:936\u2013943. https:\/\/doi.org\/10.1097\/ju.0000000000000346","journal-title":"J Urol"},{"key":"2069_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1541-0420.2007.00825.x","volume":"64","author":"D Telesca","year":"2008","unstructured":"Telesca D, Etzioni R, Gulati R (2008) Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64:10\u201319. https:\/\/doi.org\/10.1111\/j.1541-0420.2007.00825.x","journal-title":"Biometrics"},{"key":"2069_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1741-7015-12-26","volume":"12","author":"AJ Vickers","year":"2014","unstructured":"Vickers AJ et al (2014) Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 12:26. https:\/\/doi.org\/10.1186\/1741-7015-12-26","journal-title":"BMC Med"},{"key":"2069_CR4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"Grossman DC et al (2018) Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 319:1901\u20131913. https:\/\/doi.org\/10.1001\/jama.2018.3710","journal-title":"JAMA"},{"key":"2069_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003491","author":"JT Wei","year":"2023","unstructured":"Wei JT et al (2023) Early detection of prostate cancer: AUA\/SUO guideline Part I: prostate cancer screening. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003491","journal-title":"J Urol"},{"key":"2069_CR6","first-page":"70","volume":"60","author":"AM Wolf","year":"2010","unstructured":"Wolf AM et al (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60:70\u201398","journal-title":"CA Cancer J Clin"},{"key":"2069_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","volume":"21","author":"KA Moses","year":"2023","unstructured":"Moses KA et al (2023) NCCN Guidelines\u00ae Insights: prostate cancer early detection, Version 1.2023. J Natl Compr Canc Netw 21:236\u2013246. https:\/\/doi.org\/10.6004\/jnccn.2023.0014","journal-title":"J Natl Compr Canc Netw"},{"key":"2069_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8487","volume":"7","author":"KH Kensler","year":"2024","unstructured":"Kensler KH, Mao J, Davuluri M (2024) Frequency of guideline-discordant prostate cancer screening among older males. JAMA Netw Open 7:e248487","journal-title":"JAMA Netw Open"},{"key":"2069_CR9","doi-asserted-by":"publisher","first-page":"e237504","DOI":"10.1001\/jamanetworkopen.2023.7504","volume":"6","author":"S Kalavacherla","year":"2023","unstructured":"Kalavacherla S et al (2023) Low-value prostate-specific antigen screening in older males. JAMA Netw Open 6:e237504\u2013e237504","journal-title":"JAMA Netw Open"},{"key":"2069_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaoncol.2021.5143","volume":"8","author":"MS Leapman","year":"2022","unstructured":"Leapman MS et al (2022) Changes in prostate-specific antigen testing relative to the revised US preventive services task force recommendation on prostate cancer screening. JAMA Oncol 8:41\u201347. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5143","journal-title":"JAMA Oncol"},{"key":"2069_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.11.009","author":"D Dalela","year":"2024","unstructured":"Dalela D et al (2024) Prostate specific antigen screening on a nationwide level: featuring the contribution of race and life expectancy in decision making. Clin Genitourinary Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2023.11.009","journal-title":"Clin Genitourinary Cancer"},{"key":"2069_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1370\/afm.2200","volume":"16","author":"SA Fedewa","year":"2018","unstructured":"Fedewa SA et al (2018) Recent patterns in shared decision making for Prostate-Specific Antigen testing in the United States. Ann Fam Med 16:139\u2013144","journal-title":"Ann Fam Med"},{"key":"2069_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41391-020-0227-1","volume":"24","author":"C Jiang","year":"2021","unstructured":"Jiang C, Fedewa SA, Wen Y, Jemal A, Han X (2021) Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline. Prostate Cancer Prostatic Dis 24:77\u201380. https:\/\/doi.org\/10.1038\/s41391-020-0227-1","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2069_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00843-x","author":"N Bhojani","year":"2024","unstructured":"Bhojani N et al (2024) Prevalence and determinants of shared decision-making for PSA testing in the United States. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-024-00843-x","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2069_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41585-023-00840-0","volume":"21","author":"KR Pekala","year":"2024","unstructured":"Pekala KR et al (2024) Shared decision-making before prostate cancer screening decisions. Nat Rev Urol 21:329\u2013338. https:\/\/doi.org\/10.1038\/s41585-023-00840-0","journal-title":"Nat Rev Urol"},{"key":"2069_CR16","unstructured":"(CDC), C. f. D. C. a. P. (U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Georgia, 2020)."},{"key":"2069_CR17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jama.2013.1184","volume":"309","author":"M Cruz","year":"2013","unstructured":"Cruz M, Covinsky K, Widera EW, Stijacic-Cenzer I, Lee SJ (2013) Predicting 10-year mortality for older adults. JAMA 309:874\u2013876","journal-title":"JAMA"},{"key":"2069_CR18","doi-asserted-by":"publisher","first-page":"e2011645","DOI":"10.1001\/jamanetworkopen.2020.11645","volume":"3","author":"JL Moss","year":"2020","unstructured":"Moss JL et al (2020) Geographic variation in overscreening for colorectal, cervical, and breast cancer among older adults. JAMA Netw Open 3:e2011645\u2013e2011645","journal-title":"JAMA Netw Open"},{"key":"2069_CR19","doi-asserted-by":"publisher","first-page":"102492","DOI":"10.1016\/j.canep.2023.102492","volume":"88","author":"B Golijanin","year":"2024","unstructured":"Golijanin B et al (2024) \u201cShared decision-making\u201d for prostate cancer screening: Is it a marker of quality preventative healthcare? Cancer Epidemiol 88:102492. https:\/\/doi.org\/10.1016\/j.canep.2023.102492","journal-title":"Cancer Epidemiol"},{"key":"2069_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.euf.2023.04.013","volume":"9","author":"MF Basin","year":"2023","unstructured":"Basin MF et al (2023) Disparities associated with shared decision-making in prostate cancer screening. Eur Urol Focus 9:1008\u20131015. https:\/\/doi.org\/10.1016\/j.euf.2023.04.013","journal-title":"Eur Urol Focus"},{"key":"2069_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.30474","volume":"123","author":"PF Pinsky","year":"2017","unstructured":"Pinsky PF et al (2017) Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 123:592\u2013599","journal-title":"Cancer"},{"key":"2069_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J et al (2019) A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol 76:43\u201351","journal-title":"Eur Urol"},{"key":"2069_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.22454\/FamMed.2022.474827","volume":"54","author":"N Shungu","year":"2022","unstructured":"Shungu N, Diaz VA, Perkins S, Kulshreshtha A (2022) Physician attitudes and self-reported practices toward prostate cancer screening in black and white men. Fam Med 54:30","journal-title":"Fam Med"},{"key":"2069_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.07.016","author":"A Aminsharifi","year":"2018","unstructured":"Aminsharifi A et al (2018) Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in the electronic health record. Urol Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2018.07.016","journal-title":"Urol Oncol"},{"key":"2069_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1557988319834843","author":"DL Cooper","year":"2019","unstructured":"Cooper DL, Rollins L, Slocumb T, Rivers BM (2019) Are men making informed decisions according to the prostate-specific antigen test guidelines? Analysis of the 2015 behavioral risk factor surveillance system. Am J Mens Health. https:\/\/doi.org\/10.1177\/1557988319834843","journal-title":"Am J Mens Health"},{"key":"2069_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.622541","volume":"8","author":"AG Mainous 3rd","year":"2021","unstructured":"Mainous AG 3rd, Rooks BJ, Mercado ES, Carek PJ (2021) Patient provider continuity and prostate specific antigen testing: impact of continuity on receipt of a non-recommended test. Front Med (Lausanne) 8:622541","journal-title":"Front Med (Lausanne)"},{"key":"2069_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ypmed.2004.02.024","volume":"39","author":"HI Hall","year":"2004","unstructured":"Hall HI et al (2004) Testing for prostate and colorectal cancer: comparison of self-report and medical record audit. Prev Med 39:27\u201335. https:\/\/doi.org\/10.1016\/j.ypmed.2004.02.024","journal-title":"Prev Med"},{"key":"2069_CR28","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1158\/1055-9965.Epi-07-2629","volume":"17","author":"GH Rauscher","year":"2008","unstructured":"Rauscher GH, Johnson TP, Cho YI, Walk JA (2008) Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiol Biomarkers Prev 17:748\u2013757. https:\/\/doi.org\/10.1158\/1055-9965.Epi-07-2629","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2069_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.295.7.801","volume":"295","author":"SJ Lee","year":"2006","unstructured":"Lee SJ, Lindquist K, Segal MR, Covinsky KE (2006) Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295:801\u2013808","journal-title":"JAMA"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-025-02069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-025-02069-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-025-02069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:30:48Z","timestamp":1763559048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-025-02069-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2069"],"URL":"https:\/\/doi.org\/10.1007\/s10552-025-02069-1","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest with respect to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and deemed exempt by the institutional review board of Weill Cornell Medicine (Protocol 23-10036590).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"BRFSS respondents provided oral consent to complete the survey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}